Sehoon Keum
Research Subjects
Research Interests
Sehoon Keum has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- David S. Warner
Department of Anesthesiology, Duke University Medical Center, Durham, USA
1 shared publication Donald C. Lo
Center for Drug Discovery and Department of Neurobiology, Duke University Medical Center, Durham, North Carolina, USA
1 shared publication- Douglas A. Marchuk
Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, USA
1 shared publication - Han Kyu Lee
Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC (H.K.L., D.A.M.).
1 shared publication - Huaxin Sheng
Department of Anesthesiology, Duke University Medical Center, Durham, NC 27710, USA
1 shared publication
Latest Publications
- Open Access
- 11 July 2016
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 126 (8) , 2827-2838
Natural allelic variation of the IL-21 receptor modulates ischemic stroke infarct volume
Risk for ischemic stroke has a strong genetic basis, but heritable factors also contribute to the extent of damage after a stroke has occurred. We previously identified a locus on distal mouse chromosome 7 that contributes over 50% of the variation in postischemic cerebral infarct volume observed between inbred strains. Here, we used ancestral haplotype analysis to fine-map this locus to 12 candidate genes. The gene encoding the IL-21 receptor (Il21r) showed a marked difference in strain-specific transcription levels and coding variants in neonatal and adult cortical tissue. Collateral vessel connections were moderately reduced in Il21r-deficient mice, and cerebral infarct volume increased 2.3-fold, suggesting that Il21r modulates both collateral vessel anatomy and innate neuroprotection. In brain slice explants, oxygen deprivation (OD) activated apoptotic pathways and increased neuronal cell death in IL-21 receptor–deficient (IL-21R–deficient) mice compared with control animals. We determined that the neuroprotective effects of IL-21R arose from signaling through JAK/STAT pathways and upregulation of caspase 3. Thus, natural genetic variation in murine Il21r influences neuronal cell viability after ischemia by modulating receptor function and downstream signal transduction. The identification of neuroprotective genes based on naturally occurring allelic variations has the potential to inform the development of drug targets for ischemic stroke treatment.
- 11 July 2016
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 126 (8) , 2827-2838
Open AccessNatural allelic variation of the IL-21 receptor modulates ischemic stroke infarct volume
Risk for ischemic stroke has a strong genetic basis, but heritable factors also contribute to the extent of damage after a stroke has occurred. We previously identified a locus on distal mouse chromosome 7 that contributes over 50% of the variation in postischemic cerebral infarct volume observed between inbred strains. Here, we used ancestral haplotype analysis to fine-map this locus to 12 candidate genes. The gene encoding the IL-21 receptor (Il21r) showed a marked difference in strain-specific transcription levels and coding variants in neonatal and adult cortical tissue. Collateral vessel connections were moderately reduced in Il21r-deficient mice, and cerebral infarct volume increased 2.3-fold, suggesting that Il21r modulates both collateral vessel anatomy and innate neuroprotection. In brain slice explants, oxygen deprivation (OD) activated apoptotic pathways and increased neuronal cell death in IL-21 receptor–deficient (IL-21R–deficient) mice compared with control animals. We determined that the neuroprotective effects of IL-21R arose from signaling through JAK/STAT pathways and upregulation of caspase 3. Thus, natural genetic variation in murine Il21r influences neuronal cell viability after ischemia by modulating receptor function and downstream signal transduction. The identification of neuroprotective genes based on naturally occurring allelic variations has the potential to inform the development of drug targets for ischemic stroke treatment.